Deals

Thermo to Buy Qiagen for $10 Billion in 2020’s Top Health Deal

Dutch company makes tests that can detect cancer, coronavirus
Thermo Fisher expects $200 million in cost, revenue synergies

Laboratory Operations At Diagnostic Sampling Tool Manufacturer Qiagen NV — Photographer: Jasper Juinen/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Ed Hammond, Aaron Kirchfeld, and Nabila Ahmed

March 3, 2020 at 7:12 AM UTC

Updated on

March 3, 2020 at 10:59 AM UTC

This article is for subscribers only.

Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.

U.S. laboratory equipment maker Thermo Fisher Scientific Inc. agreed to buy Qiagen NV, a Dutch maker of tests for diseases including cancer and the new coronavirus, for about 9 billion euros ($10 billion) in the biggest health-care acquisition so far this year.